Neuroinflammation in Chronic Systemic Symptoms (CSS)
CompletedNCT04636723
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of the present research protocol is to investigate and identify translocator protein 18kDa, MRI DTI, and EEG/ERPs, markers of Chronic Systemic Symptoms (CSS).
Study details
- Official title
- Neuroinflammation in Chronic Systemic Symptoms (CSS): Proof-of-Concept Study Using PET and EEG/ERP Biomarkers
- Conditions
- Cancer
- Cancer Head Neck
- Neuroinflammatory Response
- Chronic Inflammation
- Chronic Disease
- Chronic Pain
- Sponsor
- Vanderbilt University Medical Center
- Collaborators
- Vanderbilt-Ingram Cancer Center
- Start date
- 2021-02-22
- Primary completion
- 2021-12-07
- Sex
- All
- Age range
- from 21 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
* Inclusion Criteria for HNC patients: * Age ≥ 21 * HNC of larynx, pharynx, oral cavity paranasal sinus, salivary gland, or unknown primary * Any histology of any epithelial origin * Completed therapy a minimum of 3 months prior to study entry * At least two systemic symptoms on the VHNSS-GSS subscale * Able to speak English to understand instructions and be able to provide informed consent * Exclusion Criteria for HNC patients: * History of neurodegenerative disease, unrelated to cancer history/treatment * Alcohol/substance abuse/dependence within the last 6 months * Current or previous co-morbid bipolar disorder-, psychosis-, obsessive compulsive disorder-, eating disorders-, personality disorders-, * Neurological disorders unrelated to cancer and its treatment (e.g. ADHD, ASDs, epilepsy) * Learning difficulties. * Inclusion Criteria for healthy controls: * Age ≥ 21 * Able to speak English to understand instructions and be able to provide informed consent * Exclusion Criteria for healthy controls: * History of HNC of larynx, pharynx, oral cavity paranasal sinus, salivary gland, or unknown primary * Alcohol/substance abuse/dependence within the last 6 months * Current or previous co-morbid bipolar disorder-, psychosis-, obsessive compulsive disorder-, eating disorders-, personality disorders-, * Neurological disorders (e.g. ADHD, ASDs, epilepsy) * Learning difficulties.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04636723